T-wave alternans

(redirected from T wave alternans)
Also found in: Wikipedia.

T-wave alternans

A repolarisation phenomenon manifesting as a microvolt beat-to-beat change in the amplitude of the T wave and ST segment on EKGs.  T-wave alternans has low specificity as a predictor of arrhythmic risk in unselected populations with prior myocardial infarction.

T-wave alternans

Cardiology A subtle every-other-beat variation in T waves that is prognostic of Pts at high risk for life-threatening cardiac arrhythmias and sudden cardiac death. See Alternans test.
References in periodicals archive ?
Explaining the clinical manifestations of T wave alternans in patients at risk for sudden cardiac death.
Objective: To compare T wave alternans in patients with cardiomyopathy and healthy controls.
Cardio Scan premier 12 lux software was used for analysis of T wave alternans.
Cardiomyopathic patients with positive T wave alternans were 13 (21.7 %) out of 60, while only 4 (6.7%) out of 60 healthy controls demonstrated positive T wave alternans.
Conclusion: The frequency of patients with cardiomyopathy having positive T wave alternans was significantly higher as compared to the healthy controls.
T wave alternans refers to a change in the contour and amplitude of T wave on every other beat1.
Olmos, "Methodological principles of T wave alternans analysis: a unified framework," IEEE Transactions on Biomedical Engineering, vol.
Computer detection of non-stationary T wave alternans using a new correlation method.
T wave alternans after sotalol: evidence for increased sensitivity to sotalol after conversion from atrial fibrillation to sinus rhythm.
Exercise is superior to pacing for T wave alternans measurement.
Assessment of micro volt T wave alternans on and off beta-blocker therapy (Abstract).
The Alternans Before Cardioverter Defibrillator (ABCD) trial: A non-invasive strategy for primary prevention of sudden cardiac death using T wave alternans. American Heart Association 2006 Scientific Sessions; 2006 November 15; Chicago, Illinois, USA; Late Breaking Clinical Trials III.